Daiichi Sankyo's COVID-19 vaccine candidate selected by Japanese drug discovery body
Daiichi Sankyo Co. said on Monday that its mRNA-based COVID-19 vaccine candidate was selected for inclusion in a drug discovery program by the Japan Agency for Medical Research and Development. The vaccine, known as DS-5670, was picked for the second round of AMED's program dedicated ...
Daiichi Sankyo sees clinical test for genetic COVID-19 vaccine in March
The vaccine contains messenger RNA that causes cells to produce proteins that could trigger the body to produce effective antibodies.
Drug devised to replace chemotherapy may reshape cancer care
A class of drugs is emerging that can attack cancer cells in the body without damaging surrounding healthy ones. They have the potential to replace chemotherapy and its disruptive side effects, reshaping the future of cancer care. The complex biological medicines, called antibody drug conjugates ...
AstraZeneca bets $6.9 billion that Daiichi Sankyo therapy will transform cancer treatment
Britain’s AstraZeneca’s biggest deal in recent memory give it access to the Japanese drugmaker’s promising but difficult to pronounce cancer treatment: trastuzumab deruxtecan.
Opioids demand rises in Japan as seniors use drugs to ease pain and improve quality of life
Selling painkillers in Japan used to be like pulling teeth. That was until baby boomers discovered how analgesics could take the sting from arthritis, diabetic nerve damage and the ravages of cancer. Now demand is taking off and drugmakers are introducing new products to a ...
Daiichi Sankyo Inc. has settled thousands of lawsuits alleging its blood-pressure drugs caused intestinal damage, bringing to $339 million the amount the drugmaker has paid over the medicines. Daiichi officials agreed Monday to pay $300 million to resolve patient suits over its blood-pressure treatments Benicar, ...
Daiichi Sankyo awarded damages over cover-up at Indian ex-subsidiary
Daiichi Sankyo Co. said Friday that an international arbitration court has ordered former shareholders of an Indian firm it acquired in 2008 to pay the drugmaker around ¥56.2 billion ($524 million) for concealing critical information. Daiichi Sankyo sold its stake in Ranbaxy Laboratories Ltd. to ...
Growth concerns loom for Daiichi Sankyo on drug warning
Daiichi Sankyo Co. risks losing a slice of revenue to generic-medicine competition next year. Now, the drugmaker's plans to fill the gap have hit a roadblock and investors worry that growth may flounder. The Tokyo-based company's best-selling medicine is set to lose patent protection in ...
Daiichi Sankyo to buy Ambit to strengthen cancer product line
Daiichi Sankyo Co. has agreed to buy U.S.-based Ambit Biosciences Corp. for as much as $410 million to bolster its pipeline of cancer treatments. The Tokyo-based drugmaker will pay $15 in cash per share, it said in a statement Monday to the Tokyo Stock Exchange. Ambit ...
